Our Mission
To develop innovative, long-acting treatment solutions that transform the lives of patients living with rare and chronic diseases — reducing the burden of frequent dosing and delivering long-lasting care.
Pioneering Long-Lasting Care
for Rare Diseases
Innovarus was founded on a simple but powerful conviction: patients with rare and chronic diseases deserve better. Too many people are burdened by frequent, painful injections — monthly or even weekly — simply because long-acting alternatives do not exist.
Our proprietary In-Situ Forming Implant (ISFI) platform addresses this directly. By reformulating proven active pharmaceutical ingredients into injectable depots that provide sustained drug release over one to twelve months, we transform existing therapies into treatments that patients can actually live with.
Our flagship product, Octavarus®, is a 3-month depot formulation of Octreotide for Acromegaly and GEP-NET — a condition currently managed with monthly injections. Octavarus® represents the first of a growing pipeline of long-acting therapies designed to redefine the standard of care.
What Guides Everything We Do
Patient-First Philosophy
Every decision at Innovarus begins and ends with the patient. We measure our success not by commercial milestones alone, but by the tangible improvement in quality of life for people living with rare and chronic diseases. Reducing the burden of frequent injections — from monthly to quarterly or even annual dosing — is not a convenience; it is a clinical imperative.
Addressing Unmet Medical Need
Rare diseases are underserved by the pharmaceutical industry. Innovarus specifically targets conditions where existing treatments are inadequate — either due to poor tolerability, inconvenient dosing schedules, or the absence of long-acting alternatives. Our ISFI platform enables us to reformulate proven therapies into superior, long-lasting products.
Scientific Excellence
Our team brings together decades of expertise in pharmaceutical formulation, clinical medicine, and drug delivery science. We apply rigorous scientific methodology at every stage — from polymer selection and formulation design through to in-vitro characterisation and pre-clinical evaluation — ensuring that every product we advance meets the highest standards of safety and efficacy.
Collaborative Innovation
Innovarus does not operate in isolation. We actively cultivate partnerships with leading academic institutions, specialist clinicians, and industry collaborators. By combining our formulation expertise with the clinical insights of our partners, we accelerate the translation of scientific discovery into real-world patient benefit.
Get in Touch
with Our Team
Whether you are a potential investor, a clinical partner, a patient organisation, or a fellow scientist — we welcome your enquiry. Our team will respond within two business days.